The Healthcare Economist on NPR
Check out my interview on NPR with Here & Now’s Jeremy Hobson about what recent changes in health insurance premiums changes mean for the future of the Affordable Care Act.
Category: My Papers
The value of adherence information
A study titled “Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia” was just published in the November edition of JMCP. This is work with co-authors Taylor T. Schwartz, Darius N. Lakdawalla, and Felicia M. Forma. The abstract is below. Go check it out! …
Evaluating Matching-Adjusted Indirect Comparisons in Practice
One of my papers on matching-adjusted indirect comparisons (MAIC) was published today, with co-authors Anshu Shrestha, Amitabh Chandra, M. Haim Erder, and Vanja Sikirica. The title is: “Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder” and the abstract is below. Check it out! Differences in patient characteristics across trials may bias efficacy estimates…
Value frameworks are here: What to do about them?
The Healthcare Economist has been published in this month’s edition of Pharmaceutical Commerce. The article, titled Value frameworks are here: What to do about them?, provides a brief overview of the existing value frameworks and describes what steps life sciences company can take to evaluate the value of their innovations. Value frameworks are here: What to do about…
Are You Just a Number?
That is the abbreviated title of a new commentary on the Forbes blog that I wrote with Tomas Philipson. The full article is HERE. An excerpt is below. New value frameworks in health care have emerged due to increasing cost pressures. Although value frameworks can be useful tools, they should be used to complement the…
Healthcare Economist in JAMA
Along with co-authors Amitabh Chandra and Ravinder Dhawan, please check out my most recent publication “Utility of Cancer Value Frameworks for Patients, Payers, and Physicians” in the latest issue of JAMA.
Preferences for Nonvalvular Atrial Fibrillation Therapies
Below is an abstract from on of my recent studies on patient and physician preferences for treatments for nonvalvular atrial fibrillation. The full article is HERE. Objectives The objective of this study was to compare patient and physician preferences for different antithrombotic therapies used to treat nonvalvular atrial fibrillation (NVAF). Methods Patients diagnosed with NVAF…
The value of surrogate endpoints for predicting real-world survival across five cancer types
You can find one of my recent papers measuring how well survival measures from clinical trials (i.e., overall survival, progression free survival, time to progression) translate into real-world survival outcomes in Current Medical Research and Opinion here. The abstract is below. Objective It is unclear how well different outcome measures in randomized controlled trials (RCTs) perform in…
The Cost of Adherence Mismeasurement: A Claims-Based Analysis
If you are attending AMCP Nexus in October, I am a co-author on a poster presentation titled “The Cost of Adherence Mismeasurement: A Claims-Based Analysis” co-authored with Felicia Forma, Ethan Scherer, Ainslie Hatch and Darius Lakdawalla. The presentation abstract is below and here. BACKGROUND: Payers often wish to measure how adherence to prescription drugs affects downstream…
AMCP Nexus Poster: Adherence Patterns for Oral Atypical Antipsychotics in Patients Diagnosed with Schizophrenia
If you are attending AMCP Nexus in October, I am a co-author on a poster presentation titled “Adherence Patterns for Oral Atypical Antipsychotics in Patients Diagnosed with Schizophrenia” co-authored with Joanna MacEwan, Felicia Forma, Ainslie Hatch and Darius Lakdawalla. The presentation abstract is below and here. BACKGROUND: Many payers rely on claims-based metrics—such as those…